Your shopping cart is currently empty

WY-50295 is an orally active and selective 5-lipoxygenase inhibitor. In rat whole blood leukocytes, WY-50295 inhibits LTB4 formation with an IC50 of 40 μM and an oral ED50 of 18 mg/kg. WY-50295 is applicable for research into asthma and other leukotriene-dependent conditions.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | WY-50295 is an orally active and selective 5-lipoxygenase inhibitor. In rat whole blood leukocytes, WY-50295 inhibits LTB4 formation with an IC50 of 40 μM and an oral ED50 of 18 mg/kg. WY-50295 is applicable for research into asthma and other leukotriene-dependent conditions. |
| Molecular Weight | 357.40 |
| Formula | C23H19NO3 |
| Cas No. | 123016-21-7 |
| Smiles | O(CC1=NC2=C(C=C1)C=CC=C2)C3=CC4=C(C=C([C@@H](C(O)=O)C)C=C4)C=C3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.